Capricor Therapeutics

Yahoo Finance • 17 days ago

Capricor signals potential commercialization of Deramiocel with $318M cash balance and FDA review milestone

Earnings Call Insights: Capricor Therapeutics (CAPR) Q4 2025 MANAGEMENT VIEW * Linda Marbán, Co-Founder, President, CEO & Director, stated the company's focus is on advancing Deramiocel for potential approval in Duchenne muscular dystr... Full story

Yahoo Finance • 17 days ago

Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Capricor Therapeutics Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026 Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoi... Full story

Yahoo Finance • 17 days ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Atkore Inc. (ATKR), Axsome Therapeutics, Inc. (AXSM), Capricor Therapeutics, Inc. (CAPR), and CTO Realty Growth, Inc. (CTO)

SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether certain officers and directors of Atkore Inc. (NYSE: ATKR), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Capricor Therapeutics, Inc. (NASDAQ: CAPR),... Full story

Yahoo Finance • 19 days ago

Sector Update: Health Care Stocks Decline Late Afternoon

Health care stocks were lower late Tuesday afternoon, with the NYSE Health Care Index shedding 0.9% PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 19 days ago

Sector Update: Health Care Stocks Mixed Tuesday Afternoon

Health care stocks were mixed Tuesday afternoon, with the NYSE Health Care Index shedding 0.2% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 19 days ago

Capricor Therapeutics Stock Gains Over New PDUFA Date For Deramiocel BLA

(RTTNews) - Capricor Therapeutics, Inc. (CAPR), Tuesday announced that the U.S. Food and Drug Administration has lifted the previously issued Complete Response Letter and resumed review of its Biologics License Application seeking full app... Full story

Yahoo Finance • 4 months ago

Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing of its underwritten public offeri... Full story

Yahoo Finance • 4 months ago

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the commencement of a proposed underwritten p... Full story

Yahoo Finance • 4 months ago

Avidity Biosciences, Inc. (RNA): A Bull Case Theory

We came across a bullish thesis on Avidity Biosciences, Inc. on BiotechBonanza’s Substack by  AnotherBio. In this article, we will summarize the bulls’ thesis on RNA. Avidity Biosciences, Inc.'s share was trading at $71.54 as of December 2... Full story

Yahoo Finance • 4 months ago

Trending tickers: Salesforce, Microsoft, Netflix, Capricor Therapeutics and Vodafone

Salesforce (CRM) Shares of Salesforce are the top trending ticker on Yahoo Finance this Thursday morning following the company’s better-than-expected earnings report, which sent the stock up nearly 3% in pre-market trading. NYSE - Delaye... Full story

Yahoo Finance • 4 months ago

Sector Update: Health Care Stocks Higher Late Afternoon

Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index up 0.5% and the He PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 months ago

Wednesday Sector Leaders: Biotechnology, Trucking Stocks

In trading on Wednesday, biotechnology shares were relative leaders, up on the day by about 4.3%. Leading the group were shares of Capricor Therapeutics, up about 352.3% and shares of Beam Therapeutics up about 11.9% on the day. Also sho... Full story

Yahoo Finance • 4 months ago

Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy

Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03 and p=0.04, respectively)Statisti... Full story

Yahoo Finance • 5 months ago

Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) breached their fiduciary duties to shar... Full story

Yahoo Finance • 5 months ago

Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

–Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development– SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Capricor Ther... Full story

Yahoo Finance • 6 months ago

CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Capricor between October 9, 2... Full story

Yahoo Finance • 6 months ago

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Capricor Therapeutics, Inc. (NASDAQ: CAPR) shareholders, concerning alleged misconduct by certain officers and directo... Full story

Yahoo Finance • 6 months ago

ROTH to Host 4th Annual Healthcare Opportunities Conference on October 9 in New York City

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan... Full story

Yahoo Finance • 6 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA resubmissionCompany preparing to resubmit CRL response under the current BLAConference call and... Full story

Yahoo Finance • 6 months ago

CAPRICOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Capricor between October 9, 2... Full story